Home » Topics » Regulatory » EMA

EMA
RSS

EMA validates MAA for Xyndari for sickle cell disease

March 13, 2018

Sigilon Therapeutics' SIG-003 awarded EMA ATMP designation

March 12, 2018

NTP-42 receives E.U., U.S. orphan designations for pulmonary arterial hypertension

March 8, 2018

Vocimagene amiretrorepvec/5-fluorocytosine granted E.U. orphan designation for glioma

March 8, 2018

EMA accepts regulatory submission for Forxiga in adults with type 1 diabetes

March 7, 2018

Gene therapy from Meiragtx receives European PRIME disgnation

March 5, 2018

EMA grants orphan drug designation to MTD-119 for hepatocellular carcinoma

March 1, 2018

EMA gives accelerated assessment to Shire's lanadelumab

Feb. 28, 2018

EMA grants orphan drug designation to cannabidiol for tuberous sclerosis

Feb. 28, 2018

EMA committee recommends change to marketing authorization terms for Feraccru

Feb. 26, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...